刘志平
  • 单位:赣南医学院   基础医学院
  • 职称:教授
  • 职位:副院长
  • 出生:1975.01
  • 性别:男
  • 社会职务: 教师

研究领域

(1) 201412  主持赣南医学院人才引进启动基金(项目编号:QD201404),资助金额:70, 20151月到20199月。

(2) 20155  主持江西省自然科学基金“Dock2在肠炎中调节宿主免疫和肠道菌落组成的机制研究”(项目编号:20151BAB205061),资助金额:5万,20157月到20186月。

(3) 20158主持国家自然科学基金 “Dock2 在宿主抗鼠类柠檬酸杆菌感染中的作用机制研究” (项目批准号:31560260),总资助金额:38万,20161月到201912月。

(4) 20161主持江西省教育厅重点项目“DNA 感受器和赣南结直肠癌患者预后的相关性研究”(项目批准号:Gjj150937), 资助金额:5万,20161月到201812月。

(5) 20161主持赣南医学院油茶专项油茶皂苷对结肠炎小鼠及巨噬细胞免疫功能的影响” (项目编号YC201501),资助金额:7万,20161月至201812月。

(6) 20167月,主持赣南油茶产业开发协同创新中心开放基金项目(项目编号YK201603)“茶油和油茶皂苷抗结肠炎和皮肤炎的应用研究”,资助金额:30万,20167月至201912月。

(7) 20161主持2015年度赣南医学院研究生优质课程建设项目“医学免疫学”,资助金额:2万,20161月到201812月。

(8) 20177主持江西省自然科学基金重点项目(项目编号20171ACB20024) DNA感受器AIM2 调节肠道菌群和细胞增殖的机制研究”,资助金额:50万,20177月到20216月。

(9) 20181主持赣南医学院“肠道炎症的发病机制”科技创新团队项目(项目编号TD201703),资助金额:30万元,20181月到202012月。

(10) 20181主持第七批江西省研究生优质课程和案例“医学免疫学”,资助金额:3万,20181月到20201月。

(11) 20181主持中央支持地方高校发展专项资金“医学免疫学”平台建设,资助金额:650万元,20181月到20201月。

(12) 20187月,主持江西省自然科学基金面上项目(项目编号20181BAB205032) DNA感受器DHX9在结直肠癌中的作用研究”,资助金额:6万元,20187月到20216月。

(13) 201810月,主持赣南医学院培育学科“医学免疫学”,资助金额:75万元,20191月到202112月。

论文与著作

1.     Xie HP, LiuZP, Zhang JS, Dai M, Xiao GM, Wu WK, Yang HZ.Traditional Chinese MedicineSyndrome Patterns and Their Association with Hepatitis B Surface Antigen Levelsduring the Natural History of Chronic Hepatitis B Virus Infection.EvidBased Complement Alternat Med. 2018; 2018:7482593.

 2.     Wu X, Wu Y, He L, Wu L, Wang X, Liu Z*. Effects of the intestinal microbial metabolite butyrateon the development of colorectal cancer. J Cancer 2018; 9(14): 2510-2517. * 通讯作者

 3.     Shi W, Li L, Ding Y, Yang K, Chen Z, Fan X, Jiang S,Guan Y, Liu Z, Xu D, Wu L.Thecritical role of epigallocatechin gallate in regulating mitochondrialmetabolism.Future Med Chem 2018 Apr 19. doi: 10.4155/fmc-2017-0204.

 4.     Zhao X#,He L#, Mao K, Chen D, Jiang H*, LiuZ*. The Research Status of Immune Checkpoint Blockade by anti-CTLA4 andanti-PD1/PD-L1 Antibodies in Tumor Immunotherapy in China: A bibliometricsstudy. Medicine 2018; 97(15):e0276.* 通讯作者

 5.     Chen Y#,Meng F#, Wang B, He L, Liu Y*, Liu Z*. Dock2 in the development of inflammationand cancer. Eur J Immunol 2018; 48(6):915-922. * 通讯作者

 6.     Yang K,Chen Z, Gao J, Shi W, Li L, Jiang S, Hu H, LiuZ, Xu D*, Wu L*. The key roles of GSK-3β in regulatingmitochondrial activity. CellPhysiol Biochem 2017; 44: 1445-1459.

 7.     Wu Y#,Wu X#, Wu L, Wang X*, Liu Z*. The anti-cancer functions of RIG-I likereceptors, RIG-I and MDA5, and their applications in cancer therapy. TranslRes 2017;190:51-60. * 通讯作者

 8.     Xiao X#,He L#, Wu L, Wang L*, Liu Z*. Anti-inflammatory and antioxidativeeffects of Camellia Oleifera Abel components. Future Med Chem 2017; 9(17):2069-2079. *通讯作者

9.     He L#,Xiao X#, Yang X, Zhang Z, Wu L*, Liu Z*. STING signaling in tumorigenesis andcancer therapy: A friend or foe? Cancer Lett 2017; 402: 203-212. * 通讯作者

 10. Wu L, Liu Z. The molecular mechanismsof preventing apoptosis of cartilage chondrocyte to target osteoarthritis. FutureMed Chem 2017; 9(6):537-540.

 11.  Yuan X, Li L, Shi W, Liu H, HuangX, Liu Z, Wu L. TMF protectschondrocytes from ER stress-induced apoptosis by down-regulating GSK-3β.BiomedPharmacother2017; 89: 1262-1268.

 12.  He L, Chen Y, Wu Y, Xu Y, Zhang Z*,Liu Z*, Nucleicacid sensing pattern recognition receptors in the development of colorectalcancer and colitis, Cell Mol Life Sci, 2017;74(13): 2395-2411. * 通讯作者

 13.  Ni T#, Li XY#,Lu N#, An T, Liu ZP,Fu R, Lv WC, Zhang YW, Xu XJ, Grant Rowe R, Lin YS, Scherer A, Feinberg T,Zheng XQ, Chen BA, Liu XS, Guo QL, Wu ZQ, Weiss SJ.Snail1-dependent p53 repressionregulates expansion and activity of tumour-initiating cells in breast cancer.Nat CellBiol2016; 18(11): 1221-1232.

 14.  Liu Z, Man SM, Zhu Q, Vogel P, Frase S, Fukui Y, KannegantiTD. DOCK2 confers immunity and intestinal colonization resistance toCitrobacter rodentium infection. Sci Rep 2016; 6, 27814.

 15.  Man SM#, Zhu Q#,Zhu L#, Liu Z#,Karki R, Malik A, Sharma D, Li L, Malireddi RK, Gurung P, Neale G, Olsen SR,Carter RA, McGoldrick DJ, Wu G, Finkelstein D, Vogel P, Gilbertson RJ,Kanneganti TD. Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferationand Cancer.Cell 2015; 162(1): 45-58.  # 共同第一作者(Comments: (1): Rommereim LM, Subramanian N.AIMing 2 Curtail Cancer. Cell. 2015; 162(1): 18-20.(2): AIM2 Blocks Colon Cancer in Three Ways.Cancer Discov. 2015; 5(9):899-900.)

 16.  Zhu Q, Man S, Gurung P, Liu Z, Vogel P, Lamkanfi M, andKanneganti TD. STING mediates protection against colorectal tumorigenesis bygoverning the magnitude of intestinal inflammation. J Immunol 2014; 193(10): 4779-82.

 17.  Lupfer CR#, Anand PK#, Liu Z, Stokes KL, Vogel P,Lamkanfi M, Kanneganti TD.ReactiveOxygen Species Regulate Caspase-11 Expression and Activation of theNon-canonical NLRP3 Inflammasome during Enteric Pathogen Infection.PLoS Pathog2014; 10(9): e1004410. #共同第一作者

 18. Wang ZX,Cao JX, Liu ZP, Cui YX, LiCY, Li D, Zhang XY, Liu JL, Li JL. Combination of chemotherapy andimmunotherapy for colon cancer in China: A meta-analysis. World J Gastroenterol 2014;20(4): 1095-1106.

 19. Syu L,El-Zaatari M,Eaton KA, Liu Z,Tetarbe M, Keeley TM, Pero J, Ferris J, Wilbert D, Kaatz A, Zheng X, Qiao X,Gumucio DL, Merchant JL, Samuelson LC and Dlugosz AA. Transgenic expression ofinterferon gamma in mouse stomach leads to inflammation, metaplasia, dysplasia,and tumorigenesis. Am J Pathol 2012; 181(6): 2114-25.

 20.  GurungP, Malireddi RK, Anand PK, Demon D, Walle LV, Liu Z, Vogel P, Lamkanfi M, Kanneganti TD.TRIF-mediatedcaspase-11 production integrates TLR4- and Nlrp3 inflammasome-mediated hostdefense against enteropathogens.J Biol Chem2012; 287(41): 34474-83.

 21.  Liu Z#,Zaki MH#, Vogel P, Gurung P, Finlay BB, Deng W, Lamkanfi M,Kanneganti TD.Therole of inflammasomes in host defense against Citrobacter rodentium infection.JBiol Chem 2012; 87(20): 16955-16964. #共同第一作者。

 22.  Liu Z,Demitrack E, Keeley TM, Eaton KA, El-Zaatari M, Merchant J and Samuelson LC. IFNγcontributes to the development of gastric epithelial cell metaplasia inHuntingtin interacting protein 1 related (Hip1r)-deficient mice. LabInvest 2012; 92(7): 1045-57.

 23.  LiuZ, Ramer-Tait A, Henderson AL,Hostetter JM, Wang C, Jergens AE, and Wannemuehler MJ. Helicobacter biliscolonization enhances susceptibility to typhlocolitis following an inflammatorytrigger. Dig Dis Sci 2011; 56(10):2838-48.

 24.  LiuZ, Sun LY. Complex roles ofSirtuin 1 in cancer and aging. TransRes 2011;157(5): 273-5.

 25.  LiuZ, Wilson-Welder JH, Hostetter JM,Jergens AE, Wannemuehler MJ. Prophylactic treatment with Hypoxishemerocallidea corm (African potato) methanolic extract ameliorates Brachyspira hyodysenteriae-inducedmurine colitis. ExpBiol Med (Maywood) 2010; 235(2):222-229.

 26.  SofiMH, Liu Z, Zhu L, Qiao Y,Chang CH. Regulation of IL-17 expression by the developmental pathway of CD4 Tcells in the thymus. Mol Immunol 2010; 47: 1262-1268.

 27.  Ye Z, Liu Z, Henderson A, Lee K, LeeS, Hostetter JM, Wannemuehler MJ and Hendrich S. Increased CYP4B1 mRNA isassociated with the inhibition of dextran sulfate sodium-induced colitis bycaffeic acid in mice. Exp Biol Med(Maywood) 2009; 234(6): 605-16.

(FeatureArticle: Caffeic Acid Inhibits Colitis in a Mouse Model—Is aDrug-Metabolizing Gene Crucial? ExpBiol Med (Maywood) 2009;234(6): VI)

 28.  LiuZ, Henderson AL, Wilson-Welder JH,Ramer-Tait A, Hostetter JM, Jergens AE, Wannemuehler MJ. Mucosal gene expression profiles followingthe colonization of immunocompetent defined flora C3H mice with Helicobacterbilis: a prelude to colitis. MicrobeInfect2009; 11(3): 374-83.

 29.  Jergens AE, Wilson Welder JH, Dorn A, Henderson A, Liu Z, Hostetter J, Evans R, and Wannemuehler MJ.Helicobacter bilis triggers persistent immune reactivity to antigensderived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut 2007;56(7):934-40.

(Commentary: Fox JG. Helicobacter bilis: bacterialprovocateur orchestrates host immune responses to commensal flora in a model ofinflammatory bowel disease. Gut2007;56(7):898-900)

 30.  Jergens AE, Dorn A, Wilson Welder J, Dingbaum K,Henderson A, Liu Z,Hostetter J, Evans RB,Wannemuehler MJ. Induction of differential immune reactivity to members ofthe flora of gnotobiotic mice following colonization with Helicobacter bilisor Brachyspira hyodysenteriae. MicrobesInfect 2006; 8(6): 1602-10.

 31.  ChenY#, Xie L#, Xie Y, Zhu J, Liu Y*, Liu Z*. Defectiveinnate and adaptive immunity against enteric bacterial infection in Dock2deficient mice. 赣南医学院学报 2018(已接受).*通讯作者.

 32.  吴新强#,熊翠#,王斐,文志勇,余文洁,王详财*刘志平*.丁酸盐抑制恶性肿瘤的作用研究进展.赣南医学院学报2018(已接受).* 通讯作者。

33.  吴新强,沈镇平,张琼,熊翠,王详财*刘志平*.DDX60在结直肠癌中表达特点的研究. 赣南医学院学报2018;38(8):739-744.* 通讯作者。

 34.  LiuX#, Wu X#, Chen Y, Qiu J, Wan T, Cao L*, Liu Z*. The effect of Tibetanmedicine Polygonum polystachyum onthe development of experimental colitis. 赣南医学院学报2018;38(4):309-313.* 通讯作者。 

35.  WangB#, Liu L#, Chen Y, Zhu J, Shen Z, Liu Z*. The effect of Camellia oil on the experimental colitis. 赣南医学院学报2018;38(3):205-209.* 通讯作者。

36.  文志勇,刘志平*,文剑波*.内镜下减重手术治疗肥胖的研究进展. 赣南医学院学报2018;38(3):265-270.* 通讯作者。

 37.  皮柔#,何良梅#,陈亚运,张桂生,朱鹃花,邹灵婕,李洪亮,刘志平*. 茶油和油茶皂苷对肠道菌群的影响. 赣南医学院学报2017; 37(6): 839-843. *通讯作者 

38. 吴源兵#,吴新强#,何良梅,王详财*刘志平*.DHX9, 恶性肿瘤治疗的新靶点?赣南医学院学报2017; 37(4): 620-625. *通讯作者

 39. 吴素珍,李加林,,刘志平*.转化生长因子-β在糖尿病肾病肾小球硬化中的作用.赣南医学院学报2017; 37(2): 312-316. *通讯作者 

40. He L,Chen Y, Wu Y, Liu Y, Zhang Z*,Liu Z*. Toll-likereceptor 9 in tumorigenesis and tumor therapy. 赣南医学院学报2017; 37(2): 169-178. *通讯作者 

41. He L#,Chen Y#, Wu Y, Liu Y, Zhang Z*,Liu Z*. Expressionprofile of Toll-like receptor 9 in colorectal cancer. 赣南医学院学报2017; 37(1): 32-37. *通讯作者 

42.  Chen Y#, Chen M#,He L, Zheng R, Liu Y*, Liu Z*. Nod-likereceptors in intestinal inflammation and cancer. 赣南医学院学报2015; 35(4):497-502. * 通讯作者

43.  刘志平、李浩、朱兰芸、刘森、薛海筹。斑点金免疫渗滤法在检测囊虫抗体中的应用。中国寄生虫学与寄生虫病杂志2001;19(6):354-356

44.  周绍慈 刘志平。应重视对持续性植物状态的研究中国航海医学杂志1998; 4(4)1